Skip to main content
Top
Published in: Journal of Contemporary Psychotherapy 1/2016

01-03-2016 | Original Paper

Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients

Author: Peter R. Breggin

Published in: Journal of Contemporary Psychotherapy | Issue 1/2016

Login to get access

Abstract

Because the epidemic dispensing of psychiatric drugs is based on misinformation, it is important for all health professionals, consumers, and most citizens (including patients and their family members) to have a more rational understanding of how psychiatric drugs actually “work.” Instead of enforcing authoritarian “medication compliance” in obedience to the prescriber’s orders, informed therapists and healthcare providers have an ethical duty to provide scientific information about the real effects of psychiatric drugs. Instead of naively accepting whatever the doctor prescribes to them, consumers need to educate themselves about all medications, but especially about psychiatric ones, which are consistently misrepresented and oversold. This review focuses on three principles of rational psychopharmacology. The first is the brain-disabling principle, which states that all psychoactive substances work by causing dysfunctions of the brain and mind. It further observes that no psychiatric drugs work by improving or correcting biochemical imbalances or any other presumed biological malfunctions. The second principle is intoxication anosognosia (medication spellbinding) which states that all psychoactive substances tend to cause a subjective over-estimation of their positive effects while masking their harmful ones, sometimes resulting in extremely harmful behaviors such as mania, violence and suicide. The third principle is chronic brain impairment (CBI)—that exposure to psychoactive substances, especially long-term, results in impairments of the brain or mind that can become persistent or permanent, including atrophy (shrinkage) of brain tissue. Not only are psychiatric drugs likely to do more harm than good, there are more effective and infinitely safer proven psychosocial approaches for treating the whole spectrum of “psychiatric disorders” from “ADHD” and “major depressive disorder” to “schizophrenia.”
Literature
go back to reference Abramson, J. (2005). Overdo$ed America. New York: Harper Perennial. Abramson, J. (2005). Overdo$ed America. New York: Harper Perennial.
go back to reference Adityanjee., Munshi, K. R., & Thampy, A. (2005). The syndrome of irreversible lithium-effectuated neurotoxicity. Clinical neuropharmacology, 28(1), 38–49.PubMedCrossRef Adityanjee., Munshi, K. R., & Thampy, A. (2005). The syndrome of irreversible lithium-effectuated neurotoxicity. Clinical neuropharmacology, 28(1), 38–49.PubMedCrossRef
go back to reference American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders, fifth edition (DSM-V). Washington, DC: American Psychiatric Association. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders, fifth edition (DSM-V). Washington, DC: American Psychiatric Association.
go back to reference Angell, M. (2004). The truth about drug companies: How they deceive us and what to do about it. New York: Harper Random House. Angell, M. (2004). The truth about drug companies: How they deceive us and what to do about it. New York: Harper Random House.
go back to reference Antonuccio, D., Danton, W., DeNelsky, G., Greenberg, R., & Gordon, J. (1999). Raising questions about antidepressants. Psychotherapy and Psychosomatics, 68, 3–14.PubMedCrossRef Antonuccio, D., Danton, W., DeNelsky, G., Greenberg, R., & Gordon, J. (1999). Raising questions about antidepressants. Psychotherapy and Psychosomatics, 68, 3–14.PubMedCrossRef
go back to reference Ballenger, J. (1995). Benzodiazepines. In A. Schatzberg & C. Nemeroff (Eds.), The American Psychiatric Press textbook of psychopharmacology (pp. 215–230). Washington, DC: American Psychiatric Press. Ballenger, J. (1995). Benzodiazepines. In A. Schatzberg & C. Nemeroff (Eds.), The American Psychiatric Press textbook of psychopharmacology (pp. 215–230). Washington, DC: American Psychiatric Press.
go back to reference Barnhart, W., Makela, E., & Latocha, M. (2004). SSRI-induced apathy syndrome: A clinical review. Journal of Psychiatric Practice, 10, 196–199.PubMedCrossRef Barnhart, W., Makela, E., & Latocha, M. (2004). SSRI-induced apathy syndrome: A clinical review. Journal of Psychiatric Practice, 10, 196–199.PubMedCrossRef
go back to reference Baughman, F, Jr, & Hovey, C. (2006). The ADHD Fraud: How psychiatry makes “patients” of normal children. Victoria, BC: Trafford Publishing. Baughman, F, Jr, & Hovey, C. (2006). The ADHD Fraud: How psychiatry makes “patients” of normal children. Victoria, BC: Trafford Publishing.
go back to reference Bockoven, S. (1963). Moral treatment in American psychiatry. New York: Springer Publishing Company.CrossRef Bockoven, S. (1963). Moral treatment in American psychiatry. New York: Springer Publishing Company.CrossRef
go back to reference Breggin, P. (1980). Brain-disabling therapies. In E. Valenstein (Ed.), The psychosurgery debate: Scientific, legal and ethical perspectives (pp. 467–505). San Francisco: Freeman. Breggin, P. (1980). Brain-disabling therapies. In E. Valenstein (Ed.), The psychosurgery debate: Scientific, legal and ethical perspectives (pp. 467–505). San Francisco: Freeman.
go back to reference Breggin, P. (1983). Psychiatric drugs: Hazards to the brain. New York: Springer. Breggin, P. (1983). Psychiatric drugs: Hazards to the brain. New York: Springer.
go back to reference Breggin, P. (1990). Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptic drugs: Evidence, etiology, implications. Journal of Mind and Behavior, 11, 425–464. Breggin, P. (1990). Brain damage, dementia and persistent cognitive dysfunction associated with neuroleptic drugs: Evidence, etiology, implications. Journal of Mind and Behavior, 11, 425–464.
go back to reference Breggin, P. (1991). Toxic Psychiatry: Why therapy, empathy and love must replace the drugs, electroshock, and biochemical theories of the ‘new psychiatry’. New York: St. Martin’s Press. Breggin, P. (1991). Toxic Psychiatry: Why therapy, empathy and love must replace the drugs, electroshock, and biochemical theories of the ‘new psychiatry’. New York: St. Martin’s Press.
go back to reference Breggin, P. (1993). Parallels between neuroleptic effects and lethargic encephalitis: The production of dyskinesias and cognitive disorders. Brain and Cognition, 23, 8–27.PubMedCrossRef Breggin, P. (1993). Parallels between neuroleptic effects and lethargic encephalitis: The production of dyskinesias and cognitive disorders. Brain and Cognition, 23, 8–27.PubMedCrossRef
go back to reference Breggin, P. (1998). Analysis of adverse behavioral effects of benzodiazepines with a discussion of drawing scientific conclusions from the FDA’s spontaneous reporting system. Journal of Mind and Behavior, 19, 21–50. Breggin, P. (1998). Analysis of adverse behavioral effects of benzodiazepines with a discussion of drawing scientific conclusions from the FDA’s spontaneous reporting system. Journal of Mind and Behavior, 19, 21–50.
go back to reference Breggin, P. (1999). Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action. International Journal of Risk and Safety in Medicine, 12, 3–35. Breggin, P. (1999). Psychostimulants in the treatment of children diagnosed with ADHD: Risks and mechanism of action. International Journal of Risk and Safety in Medicine, 12, 3–35.
go back to reference Breggin, P. (2003/2004). Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis. International Journal of Risk and Safety in Medicine, 16, 31–49. Breggin, P. (2003/2004). Suicidality, violence and mania caused by selective serotonin reuptake inhibitors (SSRIs): A review and analysis. International Journal of Risk and Safety in Medicine, 16, 31–49.
go back to reference Breggin, P. (2007). Intoxication anosognosia: The spellbinding effect of psychiatric drugs. International Journal of Risk and Safety and Medicine, 19, 3–15. Breggin, P. (2007). Intoxication anosognosia: The spellbinding effect of psychiatric drugs. International Journal of Risk and Safety and Medicine, 19, 3–15.
go back to reference Breggin, P. (2008a). Brain-disabling treatments in psychiatry: Drugs, electroshock, and the psychopharmaceutical complex (2nd ed.). New York: Springer. Breggin, P. (2008a). Brain-disabling treatments in psychiatry: Drugs, electroshock, and the psychopharmaceutical complex (2nd ed.). New York: Springer.
go back to reference Breggin, P. (2008b). Medication madness: The role of psychiatric drugs in cases of violence, suicide, and crime. New York: St. Martin’s Press. Breggin, P. (2008b). Medication madness: The role of psychiatric drugs in cases of violence, suicide, and crime. New York: St. Martin’s Press.
go back to reference Breggin, P. (2011). Psychiatric drug-induced chronic brain impairment (CBI): Implications for long-term treatment with psychiatric medication. International Journal of Risk & Safety in Medicine, 23(4), 193–200. Breggin, P. (2011). Psychiatric drug-induced chronic brain impairment (CBI): Implications for long-term treatment with psychiatric medication. International Journal of Risk & Safety in Medicine, 23(4), 193–200.
go back to reference Breggin, P. (2013). Psychiatric drug withdrawal: A guide for prescribers, therapists, patients and their families. New York: Springer. Breggin, P. (2013). Psychiatric drug withdrawal: A guide for prescribers, therapists, patients and their families. New York: Springer.
go back to reference Breggin, P. (2014a). The rights of children and parents in regard to children receiving psychiatric drugs. Children and Society, 28, 231–241.CrossRef Breggin, P. (2014a). The rights of children and parents in regard to children receiving psychiatric drugs. Children and Society, 28, 231–241.CrossRef
go back to reference Breggin, P. (2014b). Guilt, shame and anxiety: Understanding and overcoming negative emotions. Amherst, NY: Perseus Books. Breggin, P. (2014b). Guilt, shame and anxiety: Understanding and overcoming negative emotions. Amherst, NY: Perseus Books.
go back to reference Breggin, P., & Breggin, G. (2004). Talking back to Prozac. New York: St. Martin’s Press. Breggin, P., & Breggin, G. (2004). Talking back to Prozac. New York: St. Martin’s Press.
go back to reference Cade, J. (1949). Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia, 2(36), 349–352.PubMed Cade, J. (1949). Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia, 2(36), 349–352.PubMed
go back to reference Caplan, P. (1996). They say you’re crazy: How the world’s most powerful psychiatrists decide who’s normal. New York: De Capo Press. Caplan, P. (1996). They say you’re crazy: How the world’s most powerful psychiatrists decide who’s normal. New York: De Capo Press.
go back to reference Corrigan, M. W. (2012). Handbook of prosocial education. Lanham, MD: Roman and Littlefield. Corrigan, M. W. (2012). Handbook of prosocial education. Lanham, MD: Roman and Littlefield.
go back to reference Corrigan, M. W. (2014). Debunking ADHD: 10 reasons to stop drugging kids for acting like kids. Lanham, MD: Roman and Littlefield. Corrigan, M. W. (2014). Debunking ADHD: 10 reasons to stop drugging kids for acting like kids. Lanham, MD: Roman and Littlefield.
go back to reference Cosgrove, L., Krimsky, S., Vijayaraghavan, M., & Schneider, L. (2006). Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychosomatics, 76, 154–160.CrossRef Cosgrove, L., Krimsky, S., Vijayaraghavan, M., & Schneider, L. (2006). Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychosomatics, 76, 154–160.CrossRef
go back to reference Csoska, A., & Shipko, S. (2006). Persistent sexual side effects after SSRI discontinuation. Psychotherapy and Psychosomatics, 75, 187–188.CrossRef Csoska, A., & Shipko, S. (2006). Persistent sexual side effects after SSRI discontinuation. Psychotherapy and Psychosomatics, 75, 187–188.CrossRef
go back to reference Cuijpers, P., Berking, M., Andersson, G., et al. (2013a). A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Canadian Journal of Psychiatry, 58(7), 376–385. Cuijpers, P., Berking, M., Andersson, G., et al. (2013a). A meta-analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Canadian Journal of Psychiatry, 58(7), 376–385.
go back to reference Cuijpers, P., Donker, T., van Straten, A., & Andersson, G. (2010). Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. Psychological Medicine, 40, 1943–1957.PubMedCrossRef Cuijpers, P., Donker, T., van Straten, A., & Andersson, G. (2010). Is guided self-help as effective as face-to-face psychotherapy for depression and anxiety disorders? A systematic review and meta-analysis of comparative outcome studies. Psychological Medicine, 40, 1943–1957.PubMedCrossRef
go back to reference Cuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., et al. (2013b). The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: A meta-analysis of direct comparisons. World Psychiatry, 12, 137–148.PubMedPubMedCentralCrossRef Cuijpers, P., Sijbrandij, M., Koole, S. L., Andersson, G., et al. (2013b). The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: A meta-analysis of direct comparisons. World Psychiatry, 12, 137–148.PubMedPubMedCentralCrossRef
go back to reference Decker, H. (2013). The Making of DSM-III ® : A diagnostic manual’s conquest of American psychiatry. New York: Oxford University Press. Decker, H. (2013). The Making of DSM-III ® : A diagnostic manual’s conquest of American psychiatry. New York: Oxford University Press.
go back to reference Deniker, P. (1970). Introduction of neuroleptic chemotherapy into psychiatry. In F. Ayde & B. Blackwell (Eds.), Discoveries in biological psychiatry (pp. 155–164). Philadelphia: Lippincott. Deniker, P. (1970). Introduction of neuroleptic chemotherapy into psychiatry. In F. Ayde & B. Blackwell (Eds.), Discoveries in biological psychiatry (pp. 155–164). Philadelphia: Lippincott.
go back to reference El-Mallakh, R., Gao, Y., & Roberts, J. (2011). Tardive dysphoria: The role of long term antidepressant use in inducing chronic depression. Medical Hypotheses, 76, 769–773.PubMedCrossRef El-Mallakh, R., Gao, Y., & Roberts, J. (2011). Tardive dysphoria: The role of long term antidepressant use in inducing chronic depression. Medical Hypotheses, 76, 769–773.PubMedCrossRef
go back to reference Frances, A. (2014). Saving normal: An insider’s revolt against out-of-control psychiatric diagnosis: DSM-5, Big Pharma, and the Medicalization of Ordinary Life. New York: William Morrow. Frances, A. (2014). Saving normal: An insider’s revolt against out-of-control psychiatric diagnosis: DSM-5, Big Pharma, and the Medicalization of Ordinary Life. New York: William Morrow.
go back to reference Gitlin, M., Swendsen, J., Heller, T., & Hammen, C. (1995). Relapse and impairment in bipolar disorder. American Journal of Psychiatry, 152, 1635–1640.PubMedCrossRef Gitlin, M., Swendsen, J., Heller, T., & Hammen, C. (1995). Relapse and impairment in bipolar disorder. American Journal of Psychiatry, 152, 1635–1640.PubMedCrossRef
go back to reference Glenmullen, J. (2000). Prozac backlash. New York: Simon & Schuster. Glenmullen, J. (2000). Prozac backlash. New York: Simon & Schuster.
go back to reference Gøtzsche, P. C. (2013). Deadly medicines and organised crime: How big pharma has corrupted healthcare. London: Radcliffe Medical Press. Gøtzsche, P. C. (2013). Deadly medicines and organised crime: How big pharma has corrupted healthcare. London: Radcliffe Medical Press.
go back to reference Gøtzsche, P. C. (2015). Deadly psychiatry and organised denial. Copenhagen: People’s Press. Gøtzsche, P. C. (2015). Deadly psychiatry and organised denial. Copenhagen: People’s Press.
go back to reference Grahame-Smith, D. G., & Aronson, J. K. (1992). Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press. Grahame-Smith, D. G., & Aronson, J. K. (1992). Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press.
go back to reference Harrow, M., & Jobe, T. (2007). Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A fifteen year multifollow-up study. Journal of Nervous and Mental Disease, 195, 406–414.PubMed Harrow, M., & Jobe, T. (2007). Factors involved in outcome and recovery in schizophrenia patients not on antipsychotic medications: A fifteen year multifollow-up study. Journal of Nervous and Mental Disease, 195, 406–414.PubMed
go back to reference Janssen Research Foundation. (1992a, February). An integrated summary of the effectiveness of risperidone. (R 64,766). Original New Drug Application (NDA). Obtained from FDA through Freedom of Information. Janssen Research Foundation. (1992a, February). An integrated summary of the effectiveness of risperidone. (R 64,766). Original New Drug Application (NDA). Obtained from FDA through Freedom of Information.
go back to reference Janssen Research Foundation. (1992b, March). Integrated summary of information on the safety of risperidone. (R 64,766). Original New Drug Application (NDA). Obtained from FDA through Freedom of Information. Janssen Research Foundation. (1992b, March). Integrated summary of information on the safety of risperidone. (R 64,766). Original New Drug Application (NDA). Obtained from FDA through Freedom of Information.
go back to reference Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. The British Journal of Psychiatry, 188, 122–127.PubMedCrossRef Joukamaa, M., Heliövaara, M., Knekt, P., Aromaa, A., Raitasalo, R., & Lehtinen, V. (2006). Schizophrenia, neuroleptic medication and mortality. The British Journal of Psychiatry, 188, 122–127.PubMedCrossRef
go back to reference Karon, B. (2003). The tragedy of schizophrenia without psychotherapy. Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 331, 89–118.CrossRef Karon, B. (2003). The tragedy of schizophrenia without psychotherapy. Journal of the American Academy of Psychoanalysis and Dynamic Psychiatry, 331, 89–118.CrossRef
go back to reference Karon, B. (2005). Recurrent psychotic depression is treatable by psychoanalytic therapy without medication. Ethical Human Psychology and Psychiatry, 7, 45–56. Karon, B. (2005). Recurrent psychotic depression is treatable by psychoanalytic therapy without medication. Ethical Human Psychology and Psychiatry, 7, 45–56.
go back to reference Karon, B., & Vandenbos, G. (1981). The psychotherapy of schizophrenia: The treatment of choice. New York: Aronson. Karon, B., & Vandenbos, G. (1981). The psychotherapy of schizophrenia: The treatment of choice. New York: Aronson.
go back to reference Kirsch, I. (2010). The emperor’s new drugs: Exploding the antidepressant myth. New York: Basic Books. Kirsch, I. (2010). The emperor’s new drugs: Exploding the antidepressant myth. New York: Basic Books.
go back to reference Kirsch, I., Deacon, B. J., Huedo-Median, T., Scoboria, A., Moore, T., & Johnson, B. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), e45.PubMedPubMedCentralCrossRef Kirsch, I., Deacon, B. J., Huedo-Median, T., Scoboria, A., Moore, T., & Johnson, B. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLoS Medicine, 5(2), e45.PubMedPubMedCentralCrossRef
go back to reference Kutchins, H., & Kirk, S. (2003). Making Us Crazy: DSM: The Psychiatric Bible and the creation of mental disorders. New York: Free Press. Kutchins, H., & Kirk, S. (2003). Making Us Crazy: DSM: The Psychiatric Bible and the creation of mental disorders. New York: Free Press.
go back to reference Lacasse, J. R., & Leo, J. (2005). Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med, 2(12), e392.PubMedPubMedCentralCrossRef Lacasse, J. R., & Leo, J. (2005). Serotonin and depression: A disconnect between the advertisements and the scientific literature. PLoS Med, 2(12), e392.PubMedPubMedCentralCrossRef
go back to reference Lagace, D. C., & Eisch, A. J. (2005). Mood-stabilizing drugs: Are their neuroprotective aspects clinically relevant? The Psychiatric Clinics of North America, 28(2), 399–414.PubMedCrossRef Lagace, D. C., & Eisch, A. J. (2005). Mood-stabilizing drugs: Are their neuroprotective aspects clinically relevant? The Psychiatric Clinics of North America, 28(2), 399–414.PubMedCrossRef
go back to reference Leber, P. (1992). Postmarketing surveillance of adverse drug effects. In J. Kane & J. Lieberman (Eds.), Adverse effects of psychotropic drugs (pp. 3–12). New York: Guilford. Leber, P. (1992). Postmarketing surveillance of adverse drug effects. In J. Kane & J. Lieberman (Eds.), Adverse effects of psychotropic drugs (pp. 3–12). New York: Guilford.
go back to reference Lehmann, H. E., & Hanrahan, G. C. (1954). Chlorpromazine, a new inhibiting agent for psychomotor excitement and manic states. Archives of Neurology and Psychiatry, 71, 227–237.PubMedCrossRef Lehmann, H. E., & Hanrahan, G. C. (1954). Chlorpromazine, a new inhibiting agent for psychomotor excitement and manic states. Archives of Neurology and Psychiatry, 71, 227–237.PubMedCrossRef
go back to reference Lieberman, J., & Stroup, T. (2011). The NIMH-CATIE schizophrenia study: What did we learn? American Journal of Psychiatry, 168, 770–775.PubMedCrossRef Lieberman, J., & Stroup, T. (2011). The NIMH-CATIE schizophrenia study: What did we learn? American Journal of Psychiatry, 168, 770–775.PubMedCrossRef
go back to reference Lieberman, J., Stroup, T., McEvoy, J., Swartz, M., Rosenheck, R., Perkins, D., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.PubMedCrossRef Lieberman, J., Stroup, T., McEvoy, J., Swartz, M., Rosenheck, R., Perkins, D., et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.PubMedCrossRef
go back to reference Madsen, T., Treschow, A., Bengzon, J., Bolwig, T., Lindvall, O., & Tingstrom, A. (2000). Increased neurogenesis is a model of electroconvulsive therapy. Biological Psychiatry, 47, 1043–1049.PubMedCrossRef Madsen, T., Treschow, A., Bengzon, J., Bolwig, T., Lindvall, O., & Tingstrom, A. (2000). Increased neurogenesis is a model of electroconvulsive therapy. Biological Psychiatry, 47, 1043–1049.PubMedCrossRef
go back to reference Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. The Journal of Neuroscience, 20(24), 9104–9110.PubMed Malberg, J. E., Eisch, A. J., Nestler, E. J., & Duman, R. S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. The Journal of Neuroscience, 20(24), 9104–9110.PubMed
go back to reference Marangell, L., Silver, J., Goff, D., & Yudofsky, S. (2003). Pharmacology and electroconvulsive therapy. In R. Hales & S. Yudofsky (Eds.), The American Psychiatric Publishing textbook of clinical psychiatry (4th ed., pp. 1047–1149). Washington, DC: American Psychiatric Press. Marangell, L., Silver, J., Goff, D., & Yudofsky, S. (2003). Pharmacology and electroconvulsive therapy. In R. Hales & S. Yudofsky (Eds.), The American Psychiatric Publishing textbook of clinical psychiatry (4th ed., pp. 1047–1149). Washington, DC: American Psychiatric Press.
go back to reference Marks, I. M., De Albuquerque, A., Cottraux, J., Gentil, V., Greist, J., Hand, I., et al. (1989). The ‘efficacy’ of alprazolam in panic disorder and agoraphobia: A critique of recent reports. Archives of General Psychiatry, 46(7), 668–670. Marks, I. M., De Albuquerque, A., Cottraux, J., Gentil, V., Greist, J., Hand, I., et al. (1989). The ‘efficacy’ of alprazolam in panic disorder and agoraphobia: A critique of recent reports. Archives of General Psychiatry, 46(7), 668–670.
go back to reference Miller, R. (2009). Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. Current Neuropharmacology, 7, 315–330.PubMedPubMedCentralCrossRef Miller, R. (2009). Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II. Current Neuropharmacology, 7, 315–330.PubMedPubMedCentralCrossRef
go back to reference Moncrieff, J. (2007a). The myth of the chemical cure: A critique of psychiatric drug treatment. Hampshire: Palgrave Macmillan.CrossRef Moncrieff, J. (2007a). The myth of the chemical cure: A critique of psychiatric drug treatment. Hampshire: Palgrave Macmillan.CrossRef
go back to reference Moncrieff, J. (2007b). Understanding psychotropic drug action: The contribution of the brain-disabling theory. Ethical Human Psychology and Psychiatry, 9, 170–179.CrossRef Moncrieff, J. (2007b). Understanding psychotropic drug action: The contribution of the brain-disabling theory. Ethical Human Psychology and Psychiatry, 9, 170–179.CrossRef
go back to reference Moncrieff, J. (2013). The bitterest pills: The troubling story of antipsychotic drugs. New York: Palgrave.CrossRef Moncrieff, J. (2013). The bitterest pills: The troubling story of antipsychotic drugs. New York: Palgrave.CrossRef
go back to reference Morrison, A., Hutton, P., Wardle, M., Spencer, H., Barratt, S., Brabban, A., et al. (2012). Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: An exploratory trial. Psychological Medicine, 42, 1049–1056.PubMedCrossRef Morrison, A., Hutton, P., Wardle, M., Spencer, H., Barratt, S., Brabban, A., et al. (2012). Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: An exploratory trial. Psychological Medicine, 42, 1049–1056.PubMedCrossRef
go back to reference Morrison, A., Turkington, D., Pyle, M., Spencer, H., Brabban, A., Dunn, G., et al. (2014). Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: A single-blind randomized controlled trial. Lancet, 383, 1395–1403.PubMedCrossRef Morrison, A., Turkington, D., Pyle, M., Spencer, H., Brabban, A., Dunn, G., et al. (2014). Cognitive therapy for people with schizophrenia spectrum disorders not taking antipsychotic drugs: A single-blind randomized controlled trial. Lancet, 383, 1395–1403.PubMedCrossRef
go back to reference Mosher, L. (1996). Soteria: A therapeutic community for psychotic patients. In P. Breggin & E. Stern (Eds.), Psychosocial approaches to deeply disturbed persons (pp. 43–58). New York: Haworth Press. Mosher, L. (1996). Soteria: A therapeutic community for psychotic patients. In P. Breggin & E. Stern (Eds.), Psychosocial approaches to deeply disturbed persons (pp. 43–58). New York: Haworth Press.
go back to reference Mosher, L., & Bola, J. (2004). Soteria-California and its American Successors: Therapeutic ingredients. Ethical Human Psychology and Psychiatry, 6, 7–23. Mosher, L., & Bola, J. (2004). Soteria-California and its American Successors: Therapeutic ingredients. Ethical Human Psychology and Psychiatry, 6, 7–23.
go back to reference Myslobodsky, M. S. (1993). Central determinants of attention and mood disorder in tardive dyskinesia ("tardive dysmentia"). Brain and Cognition, 23(1), 88–101.PubMedCrossRef Myslobodsky, M. S. (1993). Central determinants of attention and mood disorder in tardive dyskinesia ("tardive dysmentia"). Brain and Cognition, 23(1), 88–101.PubMedCrossRef
go back to reference Myslobodsky, M. S., Tomer, R., Holden, T., Kempler, S., & Sigal, M. (1985). Cognitive impairment in patients with tardive dyskinesia. The Journal of Nervous and Mental Disease, 173(3), 156–160.PubMedCrossRef Myslobodsky, M. S., Tomer, R., Holden, T., Kempler, S., & Sigal, M. (1985). Cognitive impairment in patients with tardive dyskinesia. The Journal of Nervous and Mental Disease, 173(3), 156–160.PubMedCrossRef
go back to reference Neal, M., Gardner, C., Halberstadt, L., Kornstein, S., & Andrew, P. (2011). Blue again: Perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Frontiers in Psychology, 2011(2), 2011. doi:10.3389/fpsy.g.2011.00159. Neal, M., Gardner, C., Halberstadt, L., Kornstein, S., & Andrew, P. (2011). Blue again: Perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Frontiers in Psychology, 2011(2), 2011. doi:10.​3389/​fpsy.​g.​2011.​00159.
go back to reference Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., et al. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? International Journal of Neuropsychopharmacology, 5(2), 147–151. Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., et al. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? International Journal of Neuropsychopharmacology, 5(2), 147–151.
go back to reference Orser, B. (2007, June). Lifting the fog around anesthesia. Scientific American, pp. 54–59. Orser, B. (2007, June). Lifting the fog around anesthesia. Scientific American, pp. 54–59.
go back to reference Pachter, W., Fox, R., Zimbardo, P., & Antonuccio, D. (2007). Corporate funding and conflicts of interest: A primer for psychologists. American Psychologist, 62(9), 1005–1015.PubMedCrossRef Pachter, W., Fox, R., Zimbardo, P., & Antonuccio, D. (2007). Corporate funding and conflicts of interest: A primer for psychologists. American Psychologist, 62(9), 1005–1015.PubMedCrossRef
go back to reference Parent, Jack. (2003). Injury-induced neurogenesis in the adult mammalian brain. The Neuroscientist, 9(4), 261–272.PubMedCrossRef Parent, Jack. (2003). Injury-induced neurogenesis in the adult mammalian brain. The Neuroscientist, 9(4), 261–272.PubMedCrossRef
go back to reference Perlis, R., Ostacher, M., Patel, J., Marangell, L., Zhang, H., Wisniewski, S., et al. (2006). Predictors of recurrent in bipolar disorder: Primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry, 163, 217–224.PubMedCrossRef Perlis, R., Ostacher, M., Patel, J., Marangell, L., Zhang, H., Wisniewski, S., et al. (2006). Predictors of recurrent in bipolar disorder: Primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). American Journal of Psychiatry, 163, 217–224.PubMedCrossRef
go back to reference Pigott, H. (2011). STAR*D: A tale and trail of bias. Ethical Human Psychology and Psychiatry, 13, 6–28.CrossRef Pigott, H. (2011). STAR*D: A tale and trail of bias. Ethical Human Psychology and Psychiatry, 13, 6–28.CrossRef
go back to reference Pigott, H., Leventhal, A., Alter, G., & Boren, J. (2011). Efficacy and effectiveness of antidepressants: Current status of research. Psychotherapy and Psychosomatics, 79, 267–279.CrossRef Pigott, H., Leventhal, A., Alter, G., & Boren, J. (2011). Efficacy and effectiveness of antidepressants: Current status of research. Psychotherapy and Psychosomatics, 79, 267–279.CrossRef
go back to reference Podrabinek, A. (1979). Punitive medicine. In H. Fireside (Ed.), Soviet psychoprisons. New York: Norton. Podrabinek, A. (1979). Punitive medicine. In H. Fireside (Ed.), Soviet psychoprisons. New York: Norton.
go back to reference Randrup, A., & Munkva, I. (1967). Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia, 11, 300–310.PubMedCrossRef Randrup, A., & Munkva, I. (1967). Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia, 11, 300–310.PubMedCrossRef
go back to reference Schiorring, E. (1977). Changes in individual and social behavior induced by amphetamines and related compounds in monkeys and man. In E. H. Ellinwood Jr & M. M. Kilbey (Eds.), Cocaine and other stimulants (pp. 481–522). New York: Plenum.CrossRef Schiorring, E. (1977). Changes in individual and social behavior induced by amphetamines and related compounds in monkeys and man. In E. H. Ellinwood Jr & M. M. Kilbey (Eds.), Cocaine and other stimulants (pp. 481–522). New York: Plenum.CrossRef
go back to reference Schiorring, E. (1979). Social isolation and other behavioral changes in groups of adult vervet monkeys (Cercopithecus aethiops) produced by low, nonchronic doses of d-amphetamine. Psychopharmacology (Berl), 64, 297–302.CrossRef Schiorring, E. (1979). Social isolation and other behavioral changes in groups of adult vervet monkeys (Cercopithecus aethiops) produced by low, nonchronic doses of d-amphetamine. Psychopharmacology (Berl), 64, 297–302.CrossRef
go back to reference Seikkula, J., Aaltonen, J., Alakare, L., Haarakangas, K., Keranen, J., & Lehtinen, K. (2006). Five-year experience of first-episode nonaffective psychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. Psychotherapy Research, 16, 214–228.CrossRef Seikkula, J., Aaltonen, J., Alakare, L., Haarakangas, K., Keranen, J., & Lehtinen, K. (2006). Five-year experience of first-episode nonaffective psychosis in open-dialogue approach: Treatment principles, follow-up outcomes, and two case studies. Psychotherapy Research, 16, 214–228.CrossRef
go back to reference Seikkula, J., Alakare, B., Aaltonen, J., Holma, J., Rasinkangas, A., & Lehtinen, V. (2003). Open dialogue approach: Treatment principles and preliminary results of a two-year follow-up of first episode schizophrenia. Ethical Human Sciences and Services, 5(3), 163–182. Seikkula, J., Alakare, B., Aaltonen, J., Holma, J., Rasinkangas, A., & Lehtinen, V. (2003). Open dialogue approach: Treatment principles and preliminary results of a two-year follow-up of first episode schizophrenia. Ethical Human Sciences and Services, 5(3), 163–182.
go back to reference Swanson, J., Elliott, G., Greenhill, L., Wigal, T., Arnold, L., Vitiello, B., et al. (2007a). Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1015–1027.PubMedCrossRef Swanson, J., Elliott, G., Greenhill, L., Wigal, T., Arnold, L., Vitiello, B., et al. (2007a). Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1015–1027.PubMedCrossRef
go back to reference Swanson, J., Hinshaw, S., Arnold, L., Gibbons, R., Marcus, S., Hur, K., et al. (2007b). Second evaluation of MTA 36-month outcomes: Propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 989–1002.PubMedCrossRef Swanson, J., Hinshaw, S., Arnold, L., Gibbons, R., Marcus, S., Hur, K., et al. (2007b). Second evaluation of MTA 36-month outcomes: Propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 989–1002.PubMedCrossRef
go back to reference Tuke, S. (1996). Description of the retreat. London: Process Press. Tuke, S. (1996). Description of the retreat. London: Process Press.
go back to reference Wang, C., Zhang, M., Sun, C., Cai, Y., You, Y., Huang, L., & Liu, F. (2011). Sustained increase in adult neurogenesis in the rat hippocampal dentate gyrus after transient brain ischemia. Neuroscience Letters, 28, 70–75. Wang, C., Zhang, M., Sun, C., Cai, Y., You, Y., Huang, L., & Liu, F. (2011). Sustained increase in adult neurogenesis in the rat hippocampal dentate gyrus after transient brain ischemia. Neuroscience Letters, 28, 70–75.
go back to reference Watters, E. (2011). Crazy like us: The globalization of the American psyche. New York: Free Press. Watters, E. (2011). Crazy like us: The globalization of the American psyche. New York: Free Press.
go back to reference Weiss, M., Murray, C., Wasdell, M., Greenfield, B., Giles, L., & Hechtman, L. (2012). A randomized controlled trial of CBT therapy for adults with ADHD with and without medication. BMC Psychiatry, 12, 30.PubMedPubMedCentralCrossRef Weiss, M., Murray, C., Wasdell, M., Greenfield, B., Giles, L., & Hechtman, L. (2012). A randomized controlled trial of CBT therapy for adults with ADHD with and without medication. BMC Psychiatry, 12, 30.PubMedPubMedCentralCrossRef
go back to reference Whitaker, R. (2002). Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill. New York: Perseus. Whitaker, R. (2002). Mad in America: Bad science, bad medicine, and the enduring mistreatment of the mentally ill. New York: Perseus.
go back to reference Whitaker, R. (2010). Anatomy of an epidemic: Magic bullets, psychiatric drugs, and the astonishing rise of the mental illness in America. New York: Crown Publishers. Whitaker, R. (2010). Anatomy of an epidemic: Magic bullets, psychiatric drugs, and the astonishing rise of the mental illness in America. New York: Crown Publishers.
go back to reference Whitaker, R., & Cosgrove, L. (2015). Psychiatry under the influence: Institutional corruption, social injury, and prescriptions for reform. New York: Palgrave Macmillan.CrossRef Whitaker, R., & Cosgrove, L. (2015). Psychiatry under the influence: Institutional corruption, social injury, and prescriptions for reform. New York: Palgrave Macmillan.CrossRef
Metadata
Title
Rational Principles of Psychopharmacology for Therapists, Healthcare Providers and Clients
Author
Peter R. Breggin
Publication date
01-03-2016
Publisher
Springer US
Published in
Journal of Contemporary Psychotherapy / Issue 1/2016
Print ISSN: 0022-0116
Electronic ISSN: 1573-3564
DOI
https://doi.org/10.1007/s10879-015-9307-2

Other articles of this Issue 1/2016

Journal of Contemporary Psychotherapy 1/2016 Go to the issue